Clinical Trials
82 trialsHA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
PREeMPT
Medical College of Wisconsin
VEN+IDAC vs IDAC in AML
Guangdong Second Provincial General Hospital
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
Motixafortide for MRD Sensitization in AML
Washington University School of Medicine
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Masonic Cancer Center, University of Minnesota
Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML
Peking University People's Hospital
CIRCALL
Assistance Publique - Hôpitaux de Paris
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
LAL-2025
PETHEMA Foundation
Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Dana-Farber Cancer Institute
BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
Ruijin Hospital
FERTILAM
University Hospital, Lille
DUALFLOW
University Hospital, Bordeaux
Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study
Nanfang Hospital, Southern Medical University
ICLL07GAI
French Innovative Leukemia Organisation
HTLP-ONCO
Assistance Publique - Hôpitaux de Paris
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
Baylor College of Medicine
VERDI
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
City of Hope Medical Center
MRD-positive AML Clinical Study
Institute of Hematology & Blood Diseases Hospital, China
Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
Goethe University
Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL
University of Maryland, Baltimore
Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies
Stanford University
DARA_T_ALL
Tata Memorial Centre
Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation
First Affiliated Hospital of Zhejiang University
Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
M.D. Anderson Cancer Center
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Masonic Cancer Center, University of Minnesota
Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
Ruijin Hospital
Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant
Ohio State University Comprehensive Cancer Center
BRALLA
Instituto do Cancer do Estado de São Paulo
Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL
Hospital Universitario Dr. Jose E. Gonzalez
Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia
Therapeutic Advances in Childhood Leukemia Consortium
LAL2317
Gruppo Italiano Malattie EMatologiche dell'Adulto
VINCENT
Technische Universität Dresden
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Cedars-Sinai Medical Center
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
Beijing 302 Hospital
MRD Response-adapted Allo-HSCT for Adverse-risk AML
Peking University People's Hospital
Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML)
UNC Lineberger Comprehensive Cancer Center
Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax
Gruppo Italiano Malattie EMatologiche dell'Adulto
DLI-TARGET
Ludwig-Maximilians - University of Munich
ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT
St. Anna Kinderkrebsforschung
Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab
Zhejiang University
A Study of Chidamide With AZA in MRD Positive AML After Transplant
Guangdong Provincial People's Hospital
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
M.D. Anderson Cancer Center
Mobilising Tumour and Immune Cells Via Exercise in Chronic Lymphocytic Leukaemia
University of Bath
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
M.D. Anderson Cancer Center
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
Rutgers, The State University of New Jersey